JoVE Logo

Sign In

حساسية التنميط للعلاجات المستهدفة في المواد العضوية المشتقة من المريض NSCLC المتحورة EGFR

3.5K Views

08:52 min

November 22nd, 2021

DOI :

10.3791/63039-v

November 22nd, 2021

3,463 Views

1Department of Medicine, University of California, San Francisco, 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 3Department of Cellular and Molecular Pharmacology, University of California, San Francisco

Transcript

Explore More Videos

177 PDO NSCLC osimertinib EGFR
JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved